相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Study on the Risk Factors for Hyperuricaemia and Related Vascular Complications in Patients with Type 2 Diabetes Mellitus
Rong Shi et al.
RISK MANAGEMENT AND HEALTHCARE POLICY (2020)
Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice
Yun-hong Lu et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2020)
Uric acid and the cardio-renal effects of SGLT2 inhibitors
Clifford J. Bailey
DIABETES OBESITY & METABOLISM (2019)
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice
Amar Ali et al.
DIABETES THERAPY (2019)
Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Di Zhao et al.
JOURNAL OF HUMAN HYPERTENSION (2019)
Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis
Yakai Xin et al.
SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2019)
SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1
Aleksandra Novikov et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes
Molly G. Minze et al.
CURRENT DIABETES REVIEWS (2018)
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials
Yumo Zhao et al.
DIABETES OBESITY & METABOLISM (2018)
Interrelationship of Uric Acid, Gout, and Metabolic Syndrome: Focus on Hypertension, Cardiovascular Disease, and Insulin Resistance
Seong-Kyu Kim
JOURNAL OF RHEUMATIC DISEASES (2018)
Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus
Hala Ahmadieh et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2017)
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
K. Ogurtsova et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
Yukihiro Chino et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2014)
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
Janet B. McGill
DIABETES THERAPY (2014)
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
Sanjay Kalra
DIABETES THERAPY (2014)
Potential Role of Uric Acid in Metabolic Syndrome, Hypertension, Kidney Injury, and Cardiovascular Diseases: Is It Time for Reappraisal?
Zohreh Soltani et al.
CURRENT HYPERTENSION REPORTS (2013)
High Serum Uric Acid and Increased Risk of Type 2 Diabetes: A Systemic Review and Meta-Analysis of Prospective Cohort Studies
Qin Lv et al.
PLOS ONE (2013)
Hyperuricemia as an Independent Predictor of Vascular Complications and Mortality in Type 2 Diabetes Patients: A Meta-Analysis
Yili Xu et al.
PLOS ONE (2013)
Association Between Serum Uric Acid and Development of Type 2 Diabetes
Satoru Kodama et al.
DIABETES CARE (2009)
High Serum Uric Acid as a Novel Risk Factor for Type 2 Diabetes
Abbas Dehghan et al.
DIABETES CARE (2008)
分享论文
